{"name":"Siami, Paul F., M.D.","slug":"siami-paul-f-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pre-randomization Dutasteride","genericName":"Pre-randomization Dutasteride","slug":"pre-randomization-dutasteride","indication":"Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms","status":"marketed"}]}],"pipeline":[{"name":"Pre-randomization Dutasteride","genericName":"Pre-randomization Dutasteride","slug":"pre-randomization-dutasteride","phase":"marketed","mechanism":"Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT).","indications":["Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms","Male pattern hair loss (androgenetic alopecia)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}